now thats a good result - i was looking for a Q4 of $4m3, $53m is very strong. On full year growth - net sales were up 142% on FY12.
did they say anything on market share or rebating?
If total prescription sales are slowing like MacBank say they are - Lilly must be either taking market share or reducing the rebates for Axiron....
Would be nice to see ACR put out some further detail here!!!!
after all - they do need to justify those high salaries somehow (when Lilly is doing all the hard work selling) :-)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.001(5.56%) |
Mkt cap ! $6.931M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.9¢ | 1.7¢ | $8.809K | 495.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 266679 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 252359 | 2 |
View Market Depth
| Last trade - 14.49pm 24/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |